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Abstract
Transient thrombocytopenia is a common phenomenon 
after liver transplantation. After liver transplantation 
(LT), platelet count decreases and reaches a nadir on 
postoperative days 3-5, with an average reduction 
in platelet counts of 60%; platelet count recovers to 
preoperative levels approximately two weeks after 
LT. The putative mechanisms include haemodilution, 
decreased platelet production, increased sequestration, 
medications, infections, thrombosis, or combination 
of these processes. However, the precise mechanisms 
remain unclear. The role of platelets in liver trans-
plantation has been highlighted in recent years, and 
particular attention has been given to their effects 
beyond hemostasis and thrombosis. Previous studies 
have demonstrated that perioperative thrombocytopenia 
causes poor graft regeneration, increases the incidence 
of postoperative morbidity, and deteriorates the graft 
and decreases patient survival in both the short and 
long term after liver transplantation. Platelet therapies 
to increase perioperative platelet counts, such as thro-
mbopoietin, thrombopoietin receptor agonist, platelet 
transfusion, splenectomy, and intravenous immuno-
globulin treatment might have a potential for improving 
graft survival, however clinical trials are lacking. Further 
studies are warranted to detect direct evidence on 
whether thrombocytopenia is the cause or result of 
poor-graft function and postoperative complications, and 
to determine who needs platelet therapies in order to 
prevent postoperative complications and thus improve 
post-transplant outcomes. 
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Core tip: Transient thrombocytopenia is commonly 
seen after liver transplantation, and many studies have 
demonstrated that perioperative thrombocytopenia is 
associated with deterioration of the graft and decreased 
patient survival after liver transplantation. The role 
of platelets in liver transplantation has recently been 
highlighted, and particular attention has been given 
to their effects beyond hemostasis and thrombosis. 
Platelet therapies that increase platelet count, such 
as thrombopoietin, thrombopoietin receptor agonist, 
platelet transfusion, splenectomy, and intravenous 
immunoglobulin treatment, have a potential role for 
improving graft survival; however, clinical trials are still 
lacking, and further studies are warranted.
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INTRODUCTION
Platelets are anucleate cytoplasmic discs derived from 
megakaryocytes in the bone marrow[1-3]. The normal 
life span of platelets is 8-10 d, and they are removed 
from circulation by sequestration in the spleen[4]. 
Platelets contain three types of secretory granules: 
alpha granules, dense granules, and lysosomal 
granules. Each granule contains growth factors and 
cytokines, such as platelet-derived growth factor, 
hepatocyte growth factor (HGF), insulin-like growth 
factor-1 (IGF-1), vascular endothelial growth factor 
(VEGF), serotonin, epidermal growth factor, and 
transforming growth factor-β[5,6]. Platelets have major 
roles in hemostasis, thrombosis, inflammation, and 
vascular biology and have recently been discovered 
to have additional functions in antimicrobial defense, 
angiogenesis, tissue repair and regeneration[7-10]. 
Orthotopic liver transplantation (LT) is the treatment 
of choice for patients with end-stage liver disease and 
hepatocellular carcinoma within the Milan criteria[11,12]. 
The short and long term outcomes of this procedure 
have dramatically improved as a result of innovations in 
both immune suppression and surgical techniques[11]. 
The total number of adult LTs performed in the world 
was 27759 in 2015, of which living donor LT (LDLT) 
accounted for 21%[13]. The number of transplant 
candidates on a waiting list has also steadily increased 
despite organ shortage being a worldwide issue. 
According to the 2015 annual report from the Scientific 
Registry of Transplant Recipients, the incidence of graft 
failure in the United States continues to decrease; 
in 2014, there were 6-mo graft failure rates of 7.8% 
and 12.5% and 1-year rates of 10.3% and 15.1% in 
deceased donor LT (DDLT) and in LDLT, respectively[14].
Post-transplant thrombocytopenia occurs in the 
majority of patients immediately after LT, with reported 
incidences of up to 90%[15,16]. After LT, platelet count 
decreases and reaches a nadir on postoperative days 
(PODs) 3-5, with an average reduction in platelet counts 
of 60%; platelet count recovers to preoperative levels 
approximately two weeks after LT[17]. Thrombocytopenia 
in the postoperative period is not simply an academic 
observation but can lead to catastrophic events, such 
as postoperative bleeding, cerebral hemorrhage, 
and infection, which eventually lead to graft failure 
and mortality. The putative mechanisms involved 
include decreased platelet production, increased 
platelet consumption, sequestration in the liver graft 
or spleen, dilution, medication, or a combination of 
these processes[18-22]. However, the precise mechanism 
is still unknown. In this review, we aimed to describe 
the clinical and experimental evidence of the role 
of platelets in LT. This review differs from previous 
reviews in the following three points. First, we describe 
the role of platelets in LT specifically with a focus on 
“post-transplant thrombocytopenia”. Second, the 
involvement of platelets in DDLT and LDLT are described 
separately, since they are different in many aspects 
including the graft quality, the length of ischemia, and 
the recovery of portal hypertension after LT. Third, we 
delve into the potential mechanisms of post-transplant 
thrombocytopenia. We report previous evidence with 
consideration for future perspectives. 
PlaTeleTs aND DDlT 
Post-transplant thrombocytopenia after DDLT has 
been reported since the advent of liver transplantation 
and has been described in many articles. It was first 
reported by Hutchison et al[23] in 1968 (Table 1). They 
reviewed 8 LT recipients who received DDLT at the 
University of Colorado, which included 2 auxiliary and 
6 orthotopic LT. An acute drop in platelet count to 
less than 10 × 103/μL was observed in most patients 
within the first three postoperative days. To better 
comprehend this phenomenon, they performed 
experimental LT in dogs and found platelets located 
in the space of Disse along with Kupffer cells, some 
of which were ingesting the platelets. They concluded 
that post-transplant thrombocytopenia was primarily 
caused by the mechanical entrapment of platelets in 
the grafts, which were then destroyed by the Kupffer 
cells. The next report of this phenomenon came after 
a twenty year interval and was described by Plevak 
et al[16]. They observed that platelet counts dropped 
from preoperative levels of 137 × 103/μL to 72 × 
103/μL on POD 3. Using 111In-labeled platelets, they 
demonstrated that transplant recipients showed a 
delayed recovery of platelet counts after LT. 
Since then, several consecutive reports have been 
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published on this topic, and the majority of these 
studies indicate that postoperative thrombocytopenia 
may influence post-LT outcomes and have a negative 
impact on grafts and patient survival in the short 
and long term after LT[17,19,24-27]. McCaughan et al[17] 
reported a drop in postoperative platelet counts by 
63%, which was the only independent predictor of 
short-term patient survival post-LT. In their analysis 
of a large cohort of 541 patients of DDLT in a single 
institute, Chatzipetrou et al[24] described that a post-
transplant platelet count nadir of < 20 x 103/μL was 
associated with allograft dysfunction, graft rejection 
and poorer patient and graft survival. Chang et al[25] 
reported that the incidence of fungal infection was 
more frequent in patients with a platelet nadir of 
< 30 × 103/μL, leading to higher mortality rates. 
Sonny et al[27] focused on the elderly population and 
found that the length of intensive care unit (ICU) and 
hospital stays were longer in patients with preoperative 
platelet counts of < 45 × 103/μL. Factors such as low 
preoperative platelet counts, massive intraoperative 
platelet transfusions, retransplantation, and poor 
general preoperative conditions such as the need 
for dialysis, were found to be associated with post-
transplant thrombocytopenia[24,26]. For the treatment of 
post-transplant thrombocytopenia, Munoz et al[15] and 
Nascimbene et al[19] separately reported that an infusion 
of high-dose gamma-globulins could induce resolution 
of severe postoperative thrombocytopenia However, 
they could not explain its mechanism of action.
Recently, some groups have focused on platelet 
counts particularly on POD 5, when platelet counts 
start to rise after the nadir. In 2014, Lesurtel et al[28] 
proposed the 60-5 criteria, in which a platelet count 
of < 60 × 103/μL on POD 5 was an independent 
risk factor associated for severe postoperative 
complications, early graft failure, and patient mortality 
in the short term after DDLT. Takahashi et al[29] 
focused on the long term impact after DDLT and noted 
that a platelet count of < 72.5 × 103/μL on POD 5 
was a predictor for poor graft and patient survival. 
More recently, Takahashi et al[30] described that low 
perioperative platelet counts within 5 d after DDLT 
were associated with biliary anastomotic stricture (BAS) 
with duct-to-duct biliary reconstruction. They found 
that persistent postoperative thrombocytopenia, which 
1388 April 7, 2018|Volume 24|Issue 13|WJG|www.wjgnet.com
Table 1  Reports of postoperative thrombocytopenia after liver transplant
Author Year Type Number of patients Results
Hutchison et al[23] 1968 DDLT     8 Platelet count change from 200-400 × 103/μL to 67 × 103/μL on POD 3
Plevak et al[16] 1988 DDLT   76 Platelet count change from 137 × 103/μL to 72 × 103/μL on POD 3
Munoz et al[15] 1989 DDLT     3 Three patients with severe postoperative thrombocytopenia were 
successfully treated with high-dose gamma-globulin
McCaughan et al[17] 1992 DDLT   53 Patients who died during their hospital stay had lower postoperative 
platelet counts at the nadir, and the day of the nadir tended to be delayed
Chatzipetrou et al[24] 1999 DDLT 541 A platelet nadir of < 20 × 103/μL was associated with allograft dysfunction, 
graft rejection and poorer patient and graft survival
Chang et al[25] 2000 DDLT   50 Fungal infection was frequent in patients with a platelet nadir of < 30 × 103/μL
Ben Hamida et al[26] 2003 DDLT 161 Patients with a platelet count < 50 × 103/μL for three consecutive days 
showed a high mortality rate. 
Nascimbene et al[19] 2007 DDLT     8 Infusion of high-dose gamma-globulins induced a prompt, complete and 
persistent resolution of postoperative severe thrombocytopenia in more 
than 70% of patients
Kim et al[47] 2010 LDLT   87 A total unit of platelet transfusion was significantly associated with graft 
regeneration
Lesurtel et al[28] 2014 DDLT 247 A platelet count of < 60 × 103/μL on POD 5 was related to poor graft 
survival within 90 d after LT
Sonny et al[27] 2015 DDLT 223 A preoperative platelet count of < 45 × 103/μL was related with short-term 
outcomes in patients ≥ 60 years old
Li et al[49] 2015 LDLT 234 Patients with an immediate postoperative platelet count of < 68 × 103/μL 
had a higher chance of developing EAD and severe complications
Takahashi et al[29] 2016 DDLT 975 A platelet count of < 72.5 × 103/μL on POD 5 was related to poor graft 
survival
Han et al[48] 2016 LDLT 441 An intraoperative platelet transfusion was also independently associated 
with enhanced graft regeneration at 14 ± 2 d after surgery 
Pamecha et al[50] 2016 LDLT 120 A platelet count of < 30 × 103/μL on POD 3 was a strong predictor of 
complications and EAD
Gwiasda et al[31] 2017 DDLT 134 A higher preoperative platelet count was related to graft loss 
Takahashi et al[30] 2017 DDLT 771 Persistent thrombocytopenia within 5 d after LT was related to progression 
of biliary anastomotic stricture
Akamatsu et al[51] 2017 LDLT 445 A Low platelet count on POD 3 was an independent predictor of grade 
Ⅲb/Ⅳ complications
LT: Liver transplant; DDLT: Deceased donor liver transplant; LDLT: Living donor liver transplant; POD: Postoperative day; EAD: Early allograft 
dysfunction.
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have two ambivalent roles in LDLT. 
Kim et al[47] were the first to report the positive role 
of platelets in LDLT in 2010 (Table 1). They investigated 
the relationships between clinical variables and liver 
graft regeneration rates in their study population of 87 
recipients with adult-to-adult living donor recipients, all 
receiving right lobe grafts. They found that total units 
of platelet transfusion were significantly associated with 
graft regeneration. Han et al[48] studied the relationship 
between platelets and liver regeneration after LDLT. 
They described that intraoperative platelet transfusion 
was independently associated with enhanced graft 
regeneration at 14 ± 2 d after surgery without increasing 
morbidity and mortality rates. Furthermore, platelet 
count during the reperfusion phase was identified as a 
prognostic factor for graft regeneration. Li et al[49] focused 
on platelet count immediately after transplant and 
reported that patients with an immediate postoperative 
platelet count of < 68 × 103/μL had a higher chance 
of developing early allograft dysfunction and severe 
complications. Pamecha et al[50] demonstrated that a 
platelet count of < 30 × 103/μL on POD 3 was a strong 
predictor of major postoperative complications and was 
associated with early graft dysfunction, prolonged ascites, 
and sepsis. Akamatsu et al[51] also focused on POD 3 
and described that a low platelet count on POD 3 was an 
independent predictor of grade Ⅲb/Ⅳ complications. 
Only recently has post-transplant thrombocytopenia 
been reported to be associated with LDLT. Lower 
platelet counts lead to poor graft regeneration but lower 
incidences of ischemia-reperfusion injury in partial 
grafts. Overall higher platelets counts are beneficial 
because their impact on liver regeneration outweighs 
the associated risk of ischemia-reperfusion injury, most 
notably during the early post-LDLT period[52]. Animal 
experiments to explain this phenomenon are still 
lacking, and basic studies and prospective clinical trials 
are warranted. 
PlaTeleT fUNCTION aND 
aNTIPlaTeleT TheRaPy afTeR lT
In patients with end-stage liver disease (ESLD), platelet 
function is often reported to be compromised[53]. How-
ever, recent studies have demonstrated that platelet 
function in patients with ESLD was not as compromised 
as it was previously believed[54]. A few observational 
studies that evaluated platelet function after LT have 
been reported in the past, but these studies involved a 
small number of patients. Himmelreich et al[55] reported 
decreased platelet aggregation immediately after re-
perfusion in 10 patients after DDLT. The authors consi-
dered that a dysfunction in platelet aggregation may 
have been a major cause of intraoperative bleeding[55]. 
They also mentioned that administration of a small 
amount of University of Wisconsin (UW) solution into 
systemic circulation during reperfusion might further 
was defined as platelet counts of < 41 × 103/μL and < 
53 × 103/μL on POD 3 and POD 5, respectively, was an 
independent risk factor for BAS. 
In contrast, Gwiasda et al[31] stated that higher 
preoperative platelet count was associated with 
graft loss because platelets contribute to reperfusion 
injury after graft ischemia. Further, Eldeen et al[32] 
described that recipients who experienced early hepatic 
arterial thrombosis (HAT) had higher preoperative 
platelet counts, but this was not associated with the 
development of late HAT. 
Clinical studies suggest that increasing postoperative 
platelet counts might improve graft and patient survival 
after DDLT[28-30]. This “protective effect of platelets” may 
be compatible with a study by Hisakura et al[33] who 
showed that thrombopoietin-mediated thrombocytosis 
protected the liver from damage after an extended 
hepatectomy in a pig model. However, transplant 
surgeons prefer relatively low postoperative platelet 
counts due to fear of HAT, and this preference has made 
it difficult to perform prospective trials.
PlaTeleTs aND lDlT
After LDLT, the liver undergoes two different processes, 
namely, liver regeneration and ischemia-reperfusion[34-36]. 
The liver regeneration process after LDLT has been 
divided into three phases[34]. The early phase is rapid 
regeneration, which occurs during the first two weeks 
and is associated with vascular engorgement and tissue 
edema. The second phase is volume decline, which 
may be attributed to the normalization of transient 
vascular engorgement or tissue edema at one to two 
months after hepatectomy. The third phase is a slow 
increase in volume, which occurs until the volume 
reaches a constant level[34]. Partial liver grafts need 
rapid regeneration to meet the functional demands of 
recipients; otherwise, liver failure would occur, and the 
short- and long-term outcomes would be affected. Liver 
regeneration is orchestrated by the interplay of various 
cells and mediators, and platelets are understood 
to have a role as well[37,38]. The role of platelets in 
accelerating liver regeneration after partial hepatectomy 
was first reported by Murata in 2004[39], and Lesurtel 
et al[40] reported platelet-derived serotonin-mediated 
liver regeneration using transgenic mice. Since then, 
many studies have been reported in this field, and it was 
implicated by a Japanese group that liver regeneration 
after partial hepatectomy is promoted by platelets 
through three different mechanisms: (1) a direct effect 
on hepatocytes; (2) a cooperative effect with liver 
sinusoidal endothelial cells; and (3) a collaborative effect 
with Kupffer cells[41-45]. On the other hand, in ischemia-
reperfusion, platelets are generally considered to act 
in concert with activated Kupffer cells and leukocytes, 
and a triangular interaction between Kupffer cells, 
leukocytes, and platelets has been demonstrated to be 
the core mechanism of liver injury[46]. Thus, platelets 
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decrease platelet function[56]. Jüttner et al[57] found 
marked depressed GPⅡb/Ⅲa and P-selectin expression 
in circulating platelets, and maximum aggregation of 
platelets was restored on the third day after reperfusion 
among patients with all types of underlying disease. 
Eyraud et al[58]. conducted platelet function testing with 
aggregometry using platelet-rich plasma obtained from 
15 patients after DDLT. Compared with pre-transplant 
conditions, no significant difference was found in platelet 
function at 7 and 28 d after DDLT From these reports, 
platelet function is temporally impaired immediately after 
LT but recovers in 3-7 d. 
Regarding the use of antiplatelet therapy, some 
studies have indicated favorable effects on LT, including 
a reduced incidence of post-transplant hepatic arterial 
thrombosis[59,60] and the prevention of progression of 
liver fibrosis after postoperative recurrence of hepatitis 
C[61]. Antiplatelet therapy has also been described to 
prevent the recurrence of hepatocellular carcinoma after 
curative hepatectomy[62] and to suppress hepatocellular 
carcinogenesis in patients with chronic hepatitis[63,64]. 
However, most of these studies were performed at 
a single institution or were retrospective in nature. 
A randomized clinical trial should be undertaken to 
analyze the risks and benefits of the use of post-
transplant antiplatelet therapy.
MeChaNIsM Of POsT-TRaNsPlaNT 
ThROMbOCyTOPeNIa 
Thrombocytopenia, which is defined by a platelet count of < 
150 × 103/μL, has been reported to occur in more than 70% 
of patients with cirrhosis[65-67]. This disorder is considered 
to be a result of reduced synthesis of thrombopoietin 
(TPO) and increased sequestration by hypersplenism[67]. 
In LT, post-transplantation thrombocytopenia can occur 
due to the following: hemodilution; decreased produ-
ction of TPO; increased platelet sequestration in the 
liver graft or spleen; immunological reactions; platelet 
activation and consumption due to thrombosis, such as in 
disseminated intravascular coagulation (DIC), thrombotic 
microangiopathy, or venous thromboembolism; medication; 
infections; or a combination of these processes[18-22]. 
Hemodilution
Hemodilution due to intensive use of blood products, 
colloids and crystalloids during the transplant procedure 
may lead to a drop in the platelet count immediately 
after surgery, but the platelet nadir usually occurs on 
days 3-4, which does not validate hemodilution as a 
potential cause of postoperative thrombocytopenia. 
Preservation solution
A correlation between lower post-transplant throm-
bocytopenia and the use of UW solution was implicated 
by Williams et al[68] However, their study was an ob-
servational study that consisted of a small number of 
recipients, and the level of evidence was low[69]. 
Sequestration in the spleen 
Richards et al[20] described that patients in a hyposplenic 
state exhibit the same pattern of post-transplant 
thrombocytopenia as those with intact splenic function. 
Nascimbene et al[19] also noted that thrombocytopenia 
occurred regardless of the presence of hypersplenism. 
Thus, the spleen is not considered to be a major site of 
platelet consumption[20]. 
Consumption in the liver graft by Kupffer cells
Sindram et al[46] demonstrated that reperfusion of 
rat livers preserved for 24 h at a cold temperature 
resulted in rapid sequestration of platelets in the liver 
graft and platelet adherence to the sinusoidal lining, 
which induced apoptosis of the sinusoidal endothelial 
cells in concert with leukocytes and activated Kupffer 
cells. Cywes et al[18] detected significantly increased 
adherence of platelets to the hepatic endothelium after 
reperfusion of the liver graft. Porte et al[70] reported that 
thrombocytopenia started immediately after reperfusion, 
and sequestration of platelets was observed as platelets 
accumulated in the sinusoids and were phagocytized 
by Kupffer cells, which was similar to an earlier study. 
On the other hand, Takahashi et al[41] suggested that 
platelets that accumulate in the liver graft have with 
contact with Kupffer cells and release growth factors, 
such as HGF, IGF-1, and VEGF, that protect the liver 
graft and lead to improved graft survival in patients with 
higher platelet counts after DDLT[29].
Consumption at the liver graft with local thrombin 
generation
Richards et al[20] found that the levels of fibrin and 
fibrinogen degradation products are elevated posto-
peratively, which they speculated was due to endothelial 
damage in the liver graft during the preservation 
period, which lead to hepatic sequestration due to 
local thrombin generation. Nobuoka et al[71] focused on 
activity of a disintegrin-like and metalloproteinase with 
thrombospondin type-1 motifs member 13 (ADAMTS13), 
which is produced by stellate cells. ADAMTS13 is 
an enzyme that specifically cleaves multimetric von 
Willebrand factor (vWF), which mediates the adhesion of 
platelets to the site of vascular damage. They described 
that decreased activity of ADAMTS13 accompanied 
by elevated vWF levels was associated with throm-
bocytopenia 2 wk after LDLT. They considered that 
prolonged thrombocytopenia after LDLT was due to 
decreased production of ADAMTS13 in the graft with 
local thrombin generation and platelet aggregation. 
Nakanuma et al[72] found that platelet aggregation 
was mainly present at zone 3 in the liver graft as 
extravasated platelet aggregation (EPA), and peripheral 
platelet counts were lower after LDLT in the EPA-
positive patients than the EPA-negative patients. They 
considered that EPA in the zone 3 caused the platelet 
consumption, activation, and degranulation, following 
the release of negative cytokines by platelets, and 
Takahashi K et al . Thrombocytopenia after liver transplantation
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might be involved in liver damage and poor outcomes 
after LDLT[72]. 
TPO production
Serum TPO concentration is inversely related to 
platelet concentration in patients with hematopoietic 
disorders characterized by deceased megakaryocytes 
in the bone marrow[5]. The level of expression of mRNA 
for TPO is high in the liver, indicating that the liver is 
the main source of TPO synthesis[73]. 
Richards et al[74] reported that thrombocytopenia 
following LT was accompanied by an increased rate of 
thrombopoiesis in the early period after transplantation, 
shown by increased reticulated platelets following the 
platelet nadir. Peck-Radosavljevic et al[75] observed that 
serum thrombopoietin levels increased significantly 
on the first day after LT, which preceded the increase 
in reticulated platelets by 3 d and in peripheral 
platelets by 5 d. This delayed rise in platelet count was 
compatible with the time lag between the appearance of 
reticulated platelets and peripheral platelets after in vivo 
administration of a recombinant human thrombopoietin 
analogue, and rules out the impaired production of TPO 
as a possible cause of post-transplant thrombocytopenia. 
Usui et al[76] reported the TPO levels in the prolonged 
thrombocytopenic group were significantly decreased. 
They considered that prolonged post-transplant 
thrombocytopenia was secondary to a decrease in TPO 
production suggesting graft dysfunction. 
Medication
Immunosuppressive medications (e.g., azathioprine, myco-
phenolate mofetil, cyclosporine and tacrolimus), heparin, 
anti-thymocyte globulin (ATG), antiviral drugs (ganciclovir 
and valganciclovir), trimethoprim sulfamethoxazole, etc., 
can cause thrombocytopenia after LT. Antimetabolites, 
such as azathioprine and mycophenolate mofetil, have 
myelosuppressive effects on the bone marrow in a dose-
dependent manner[77,78]. Nascimbene et al[19] performed 
bone marrow aspirates during the early post-LT period 
and noticed marked megakaryocytic hyperplasia in all 
cases, ruling out drug-induced myelosuppression as a 
cause of post-transplant thrombocytopenia. Calcineurin 
inhibitors, such as cyclosporine and tacrolimus, may 
cause thrombocytopenia. The presentation is similar to 
thrombotic thrombocytopenic purpura (TTP), in which renal 
dysfunction is accompanied by thrombocytopenia[79-81]. 
Lee et al[79] described that the incidence of cyclosporine-
induced TTP was low (incidence of 1%) and was seen only 
in the pediatric population, occurring at 2 to 30 wk after 
LT. 
Heparin-induced thrombocytopenia (HIT) after LT 
has been reported in several articles[22,82-85]. Kaneko 
et al[22] demonstrated that the percentage of heparin-
induced thrombocytopenia (HIT) antibody-positive 
patients was low (incidence of 5.6%), and none of 
the patients developed HIT. Bakchoul et al[82] also 
described that HIT was clinically suspected in 16% 
of recipients at a median of POD 6. However, only 
one of these patients was positive for anti-platelet 
factor 4/heparin IgG antibodies. ATG induces dose-
dependent T-cell depletion by complement-dependent 
cytotoxicity, antibody-dependent cellular cytotoxicity, 
and apoptosis[86,87]. ATG-induced platelet aggregation 
is a specific reaction responsible for thrombocytopenia. 
Platelet surface antigen-CD32 has been suggested to 
play a crucial role in ATG-induced thrombocytopenia[88]. 
Ganciclovir and valganciclovir are suspected to have 
direct bone marrow toxicity. Gabardi et al[89] reported 
that the incidence of thrombocytopenia with low-dose 
valganciclovir, used as prophylaxis for cytomegalovirus 
(CMV) infections in post-transplant patients, was 
24%. Trimethoprim sulfamethoxazole, when used as 
prophylaxis against Pneumocystis jiroveci pneumonia, 
causes drug-induced immune thrombocytopenia (ITP) 
by antibody formation[90]. 
ITP and infection
Viral infections, including CMV, Epstein-Barr virus (EBV), 
parvovirus B19, herpes zoster, human herpes virus 8, 
and some donor-derived viral infections, can induce 
ITP[91-97]. The early onset of ITP after LT occurs due to 
reactivation of CMV, EBV or varicella infection when 
patients are receiving high-dose immunosuppression. 
On the other hand, Taylor et al[21] reported 8 cases of ITP 
after LT (incidence of 0.7%), in which they could not find 
any evidence of infection. The majority of their patients 
developed ITP more than one year post-LT. Maar et al[98] 
described that recipients with CMV infection showed 
delayed thrombocytopenia, occurring later than 24 d 
after LT. They considered that CMV infection induced 
systemic endothelial activation with the expression of 
tissue factor on the endothelial cell surface and the 
release of vWF. These processes activate the clotting 
cascade and may augment platelet aggregation.
Considering that post-transplant thrombocytopenia 
mostly occurs during the early period after LT, se-
questration in the new liver graft has the strongest 
potential to explain the temporal drop in platelet counts. 
However, the precise mechanism of sequestration is still 
unknown. Prolonged thrombocytopenia, which occurs 
more than one month after LT, may be attributed to 
other causes such as impaired TPO production due to 
graft dysfunction, viral infections, and medications. 
PlaTeleTs aND TRaNsfUsION
The median blood loss associated with LT has fallen 
dramatically with the development of surgical and 
anesthetic techniques. However, there are still a number 
of patients who require significant amounts of blood 
products perioperatively. 
DDLT
In 1989, Miyata et al[99] described that there was 
positive correlation between the number of platelet 
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units transfused and endotoxin concentrations at the 
end of the anhepatic phase, which they considered to 
be the reason for increased pulmonary complications. 
de Boer et al[100] demonstrated that intraoperative 
platelet transfusion was an independent risk factor for 
one- and five-year survival after DDLT. A subsequent 
report from Pereboom et al[101] noted that platelet 
transfusion led to an increased one-year mortality 
from acute lung injury. More recently, Chin et al[102] 
reported that graft survival was reduced significantly in 
patients receiving intraoperative platelet transfusions 
at one year, but not at 90 d, and considered that 
intraoperative transfusion and not thrombocytopenia 
was associated with a poor outcome after LT. They 
found a relationship between intraoperative platelet 
transfusion and postoperative septicemia as a cause of 
death. Nacoti et al[103] focused on a pediatric population 
and found that platelet transfusion was an independent 
risk factor for developing major complications in the 
first year after DDLT. In contrast, Nixon et al[104] found 
that there was no substantiated effect of platelet 
transfusion on survival after LT, due to their use of 
plateletpheresis. They insisted on using single-donor 
platelet transfusions rather than random donor platelet 
preparations, along with leucocyte reduction strategies.
LDLT
Authors from two different institutes in South Korea 
described that platelet transfusion after LDLT was a 
protective factor for graft regeneration and survival[47,48]. 
Li et al[105] described that although massive red blood 
transfusion led to poor long-term survival, higher 
postoperative infection rates and prolonged ICU stays, 
platelet transfusion was not a risk factor for long-term 
graft survival.
Thromboelastography
With the hope of limiting the use of blood products, 
some transplant centers use thromboelastography 
(TEG) to monitor and detect coagulopathies[106]. TEG 
is a viscoelastic test that is performed on whole blood 
to analyze complete hemostasis, from platelet plug 
formation through coagulation and fibrinolysis. There 
is growing evidence to support the use of TEG as a 
technique to guide transfusion strategies for LT[107-109]. 
Kang et al[109] prospectively validated the use of TEG 
for reducing total blood product use. Lawson et al[107] 
described that the maximum amplitude measured 
preoperatively by TEG had high predictability for 
intraoperative massive transfusion. Krzanicki et al[110] 
performed a retrospective review of 124 DDLT recipients 
and found a higher incidence of a hypercoagulable state 
in patients with a background of cholestatic diseases 
and an intraoperative hypercoagulable state that 
was correlated with early HAT after LT. On the other 
hand, Wikkelsoe et al[111] performed a systemic review 
and meta-analysis including a sequential analysis of 
randomized clinical trials of a TEG/thromboelastometry-
based algorithm compared with standard treatment in 
patients with cardiac surgery and LT, and found that the 
former had no impact on mortality, the amount of blood 
transfused, or the incidence of surgical reinterventions. 
There was a significant difference in the impact of 
platelet transfusion between DDLT and LDLT, the former 
being negative, and the latter being positive. The reason 
for this difference could be due to graft type; partial 
grafts require postoperative liver regeneration. This 
result is compatible with a report from Matsuo et al[44] 
that transfusion of platelet-rich plasma accelerated 
liver regeneration, including liver/body weight ratio 
and hepatocyte Ki-67 labeling index during the early 
phase after hepatectomy in a rat model. However, it 
is still unknown how platelets interact with other cells 
when under ischemia-reperfusion conditions. The 
precise mechanisms need to be clarified by animal 
experiments. TEG may be a good option to stratify the 
risk of perioperative transfusions. However, it is still 
debated whether the use of TEG is realistically efficient 
for predicting the need for transfusions. 
PlaTeleT, lT aND sPleNeCTOMy
Splenectomy is currently one of the therapeutic 
procedures for avoiding small-for-size syndrome, and 
it is a choice for preventing postoperative thrombo-
cytopenia in LDLT[112,113]. It has been indicated for the 
completion of post-transplant interferon therapy for 
hepatitis C virus (HCV) infection and ABO incompati-
ble LT[113,114]. However, due to recent advances in 
interferon (INF)-free direct-acting antivirals for HCV 
infection and rituximab induction for ABO incompati-
ble transplantation, the necessity for splenectomy is 
currently decreasing[114]. Partial splenic embolization is 
a minimally invasive treatment that can be performed 
as an additional treatment after LT; however, its efficacy 
may be insufficient, and serious complications, such as 
splenic abscess, splenic rupture, and venous thrombosis, 
have been reported[115]. On the other hand, simultaneous 
splenectomy in DDLT is not usually performed based on 
historical reports of septic complications after LT[116].
Marubashi et al[112] revealed that 7 patients who 
underwent a simultaneous splenectomy showed remar-
kable increases in platelet counts 2 wk after LDLT and 
found that graft size was positively associated with 
post-transplant thrombocytopenia. Morimoto et al[117] 
demonstrated that with simultaneous splenectomy, the 
platelet count increased to > 100 × 103/μL one month 
post-transplantation in recipients with HCV infection and 
achieved better sustained virological response after INF 
therapy. Additionally, a similar report by Chu et al[114] 
noted that patients with simultaneous splenectomy 
had significantly higher platelet counts at 1 and 6 
mo after transplantation, with a higher HCV anti-
therapy completion rate. On the other hand, Ito et al[116] 
observed that simultaneous splenectomy increased 
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platelet count more than 2 wk after LDLT but not 
during the early postoperative period. In addition, the 
incidence of reoperation for postoperative hemorrhage 
increased within the first week. The authors further 
demonstrated that simultaneous splenectomy was an 
independent predictor for postoperative lethal infectious 
complications. On the other hand, Takahashi et al[118] 
described the usefulness of pre-transplant splenectomy 
in pediatric recipients suffering from biliary atresia. 
After splenectomy, the platelet count was significantly 
elevated, with an improvement in the PT-INR and 
Model for End-Stage Liver Disease score. However, the 
complication rate for this procedure was relatively high. 
The effect of splenectomy on restoring posto-
perative platelet counts during the early post-LT 
period may be delayed from the time when a higher 
platelet count is necessary. This issue may be resolved 
by pre-transplant splenectomy, which can elevate 
preoperative platelet counts. However, the decision to 
perform pre-transplant splenectomy should be given 
much care and consideration due to the poor general 
condition of the patients and their bleeding tendencies.
fUTURe PeRsPeCTIves
TPO[33,43,45,119,120], TPO receptor agonists[121], artificial 
platelets[122,123], and freeze-dried platelets[124] are 
developing and beginning to be utilized in various clinical 
settings, and the importance of platelets is becoming 
more obvious. Additionally, the infusion of high-dose 
immunoglobulins may provide a safe, prompt, complete, 
and persistent resolution of severe post-transplant 
thrombocytopenia[15,19]. These platelet therapies, sple-
nectomy and intravenous immunoglobulin treatment 
may have potential as therapeutic strategies to resolve 
post-transplant thrombocytopenia, leading to improved 
graft and patient survival after LT. In particular in LDLT, 
these strategies may be able to prevent small-for-size 
syndrome by promoting liver regeneration[47,48,112,118]. 
However, decreases in platelet count are sometimes 
falsely overestimated by automatic analyzers due to 
platelet aggregation. Therefore, manual counting to 
confirm a platelet reduction before initiating platelet 
therapies and monitoring precise platelet counts after 
therapy are necessary. 
lIMITaTIONs
We acknowledge there are limitations to this review. 
First, most studies are based on small retrospective 
series from single institutions. The reason for this 
is there is still no consensus regarding the role of 
platelets in LT (i.e., “Are platelets a friend or foe in 
LT?”). This fact has led to difficulty in conducting 
multi-institutional prospective trials to clarify the role 
of platelets in LT. Second, it is still difficult to prove 
whether thrombocytopenia is a “result” or a “cause” of 
postoperative complications. Many studies describe post-
transplant thrombocytopenia as a phenomenon, but 
there has been no direct evidence that show whether 
thrombocytopenia is a cause or a result of poor graft 
function or complications. It is necessary to clarify this 
important point with basic animal experiments. Third, 
since thrombocytopenia is common after LT, it is still 
unclear how to determine which patients need platelet 
therapies to prevent postoperative complications and 
yield better outcomes. By conducting multi-institutional 
prospective trials, it is important to generate a 
standardized cut-off value to specify the target patients 
for platelet therapies. 
CONClUsION
We described convincing evidence of post-transplant 
thrombocytopenia and the role of platelets in LT and 
discussed future perspectives. The mechanisms of 
thrombocytopenia and its effect on postoperative 
outcomes are still not completely understood. Since 
platelets have both beneficial and detrimental effects 
on liver grafts, therapeutic strategies to increase 
perioperative platelet counts, such as the use of throm-
bopoietin, thrombopoietin receptor agonist, platelet 
transfusion, splenectomy, and intravenous immuno-
globulin treatment, could be targeted to enhance the 
beneficial effects while minimizing potential detrimental 
effects.
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